SB

Sheel Biotech Ltd

Q2 FY27

Sheel Biotech Q2 Results 2026 (FY27): Revenue ₹50.56 Cr, EBITDA margin 11.67%

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Based on Sheel Biotech Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹61
Market cap₹124 Cr
P/E8.3

The short version

Revenue from Operations (H1 FY2027): ₹50.56 Crore vs. EBITDA for H1 FY2027: ₹589.76 Lakhs, up 208.31% YoY from ₹191.29 Lakhs.

From Sheel Biotech Ltd's Q2 FY27 earnings-call transcript · updated 17 Nov 2026.

How did Sheel Biotech's revenue grow in the September 2026 quarter?

  • Revenue from Operations (H1 FY2027): ₹50.56 Crore vs. ₹21.85 Crore (H1 FY2026), up 131.39% YoY (Page 5)
  • Total Income (H1 FY2027): ₹50.88 Crore vs. ₹21.99 Crore (H1 FY2026), up 131.33% YoY (Page 5)
  • Outlook:

2 more points from Sheel Biotech Ltd's call on revenue

Create a free account to keep reading this call

What happened to Sheel Biotech's margins in Q2 FY27?

See what Sheel Biotech Ltd said on profitability & margins — free account, 30 seconds.

What capex is Sheel Biotech planning?

  • Blueberry Commercial Expansion (FY27–28): Expand contracted farm acreage, scale tissue culture production of blueberry plants domestically, strengthen cold chain and post-harvest handling capacity dedicated to berries, deepen FPO network deployment for contract blueberry farming.
  • Status: Institutional orders secured for blueberry projects in Jammu & Kashmir and Himachal Pradesh (H1 FY27).
  • Infrastructure: Pilkhuwa, UP facility includes a live blueberry demo farm and offers integrated Greenhouse + Aeroponic + Hydroponic + Packhouse facilities.
  • Tissue culture production capacity: 1.5 Crore plants/year, re-orientable to blueberries as demand scales.

2 more points from Sheel Biotech Ltd's call on capex

Create a free account to keep reading this call

Is Sheel Biotech raising money or cutting debt?

See what Sheel Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Sheel Biotech's order book?

  • The presentation reports a combined announced project value of ₹35.92 Crore comprising:
  • ₹21.39 Crore Jammu & Kashmir Precision Farming Project focused on setting up 5 Centres of Excellence for Precision Farming across 5 districts of Jammu & Kashmir, executed on a turnkey basis.
  • ₹14.53 Crore Blueberry Growing Infrastructure Project, including infrastructure and growing systems for blueberry cultivation.
  • Received Letter of Allotment from J&K Agro Industries Development Corporation Limited (JKAIDCL) for the Jammu & Kashmir Precision Farming Project.

2 more points from Sheel Biotech Ltd's call on order book

Create a free account to keep reading this call

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sheel Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sheel Biotech Ltd Q2 FY27 results?

Revenue from Operations (H1 FY2027): ₹50.56 Crore vs. EBITDA for H1 FY2027: ₹589.76 Lakhs, up 208.31% YoY from ₹191.29 Lakhs.

What is Sheel Biotech Ltd share price analysis?

Sheel Biotech Ltd currently shows a neutral. The stock trades at a P/E of 8.3 with a market cap of ₹124 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sheel Biotech Ltd planning capital expenditure?

Blueberry Commercial Expansion (FY27–28): Expand contracted farm acreage, scale tissue culture production of blueberry plants domestically, strengthen cold chain and post-harvest handling capacity ded.

Keep Sheel Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.